Literature DB >> 17591046

Bax upregulation may provide a rationale for the low incidence of esophageal adenocarcinoma in a Greek cohort of patients with Barrett's esophagus.

Dimitrios Chatzopoulos1, Athanasios Kyrgidis, Jannis Kountouras, Christos Zavos, Epaminondas Molyvas, Ioannis Venizelos.   

Abstract

BACKGROUND/AIMS: Previously rare, esophageal adenocarcinoma (EA) is now the most common esophageal malignancy in Western countries whose incidence is increasing faster than any other cancer. However, mortality from esophageal cancer in Greece is among the lowest in the world and no clear-cut answer has emerged as to why the incidence of EA is so low in this country. Thus, the aim of the study was to provide an explanation for the low incidence of EA in Greece through molecular-based ethnic differentiations.
METHODOLOGY: Out of 270 patients who underwent upper gastrointestinal endoscopic and histologic evaluation due to GERD symptoms, 31 patients (23 males, 8 females, mean age 47.10 +/- 11.88 years) with BE (typical salmon-pink lesions) and 21 GERD controls (12 males, 9 females, mean age 46.57 +/- 17.71 years) were ultimately included in the study. Esophageal mucosa biopsy specimens were evaluated immunohistochemically for Ki-67, Bax and Bcl-2 expressions.
RESULTS: Increased expression of Ki-67 was observed in BE patients compared with GERD controls (p = 0.01); increased expression of Bax was noticed in the total BE patients compared with GERD controls (p < 0.001); Bcl-2 expression did not differ between the two groups.
CONCLUSIONS: Our findings indicate a possible existence of a balance between cell proliferation (indicated by Ki-67 increased expression) and apoptosis (indicated by Bax protein overexpression), thereby providing an equilibrium between cell apoptosis and cell proliferation, and this may partly explain the low EA incidence in Greece.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17591046

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  6 in total

1.  New evidence on bisphosphonate related osteonecrosis of the jaws suggests dental referral prior to commencement of treatment.

Authors:  A Kyrgidis; St Triaridis; K Vahtsevanos
Journal:  Hippokratia       Date:  2009-01       Impact factor: 0.471

2.  Comparison of COX-2, Ki-67, and BCL-2 expression in normal esophageal mucosa, Barrett's esophagus, dysplasia, and adenocarcinoma with postablation mucosa and implications for ablative therapies.

Authors:  Christopher John Lewis; Sri Ganeshamurthy Thrumurthy; Susan Pritchard; Gordon Armstrong; Stephen Edwin Arthur Attwood
Journal:  Surg Endosc       Date:  2011-02-27       Impact factor: 4.584

3.  Ki-67 and Bax expression in esophageal mucosa might have implications in ablative therapies for Barrett's esophagus, dysplasia, and adenocarcinoma.

Authors:  Jannis Kountouras; Dimitrios Chatzopoulos; Christos Zavos; Georgia Deretzi; Stergios A Polyzos; Emmanuel Gavalas; Philippos Klonizakis; Elizabeth Vardaka; Panagiotis Katsinelos; Christos Stergiopoulos; John Moschos; Evaggelia Giartza-Taxidou
Journal:  Surg Endosc       Date:  2012-01       Impact factor: 4.584

4.  Reply to letter to the editor: Re: Comparison of COX-2, Ki-67, and BCL-2 expression in normal esophageal mucosa, Barrett's esophagus, dysplasia, and adenocarcinoma with postablation mucosa and implications for ablative therapies (Online First).

Authors:  Sri Ganeshamurthy Thrumurthy; Christopher John Lewis; Susan Pritchard; Gordon Armstrong; Stephen Edwin Arthur Attwood
Journal:  Surg Endosc       Date:  2012-01       Impact factor: 4.584

5.  Prevalence of Barrett's esophagus in Northern Greece: A Prospective Study (Barrett's esophagus).

Authors:  P Katsinelos; G Lazaraki; J Kountouras; G Chatzimavroudis; C Zavos; S Terzoudis; E Tsiaousi; S Gkagkalis; C Trakatelli; A Bellou; T Vasiliadis
Journal:  Hippokratia       Date:  2013-01       Impact factor: 0.471

6.  The histological and immunohistochemical aspects of bile reflux in patients with gastroesophageal reflux disease.

Authors:  Andreas Nakos; Georgios Kouklakis; Michail Pitiakoudis; Petros Zezos; Eleni Efraimidou; Alexandra Giatromanolaki; Alexandros Polychronidis; Nikolaos Liratzopoulos; Efthimios Sivridis; Konstantinos Simopoulos
Journal:  Gastroenterol Res Pract       Date:  2011-07-24       Impact factor: 2.260

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.